The U.S. FDA has approved Celcuity’s drug for an advanced form of breast cancer, the regulator said on Tuesday, making it the company’s first product to gain market entry and sending its shares up seven per cent in afternoon trading.
The U.S. Food and Drug Administration’s approval was based on late-stage data showing the drug, gedatolisib, branded as Revtorpyk, when combined with Pfizer’s Ibrance and fulvestrant, reduced the risk of disease progression or death by 76 per cent compared with fulvestrant alone.
Get weekly health news
Receive the latest medical news and health information delivered to you every Sunday.
Revtorpyk is intended to treat patients with advanced breast cancer whose tumors have low levels of a protein called HER2 and no mutation in a gene called PIK3CA, and whose disease has worsened after hormone therapy and a CDK inhibitor, a type of therapy.
Patients receiving the combination remained progression-free for a median of 9.3 months, compared with 2.0 months for patients receiving fulvestrant alone.
